Primary tumor organoids are a robust model of individual human cancers and present a
unique platform for patient-specific drug testing. Optical imaging is uniquely suited to assess …

There is a need for technologies to predict the efficacy of cancer treatment in individual
patients. Here, we show that optical metabolic imaging of organoids derived from primary …

Objectives Three-dimensional organoids derived from primary pancreatic ductal
adenocarcinomas are an attractive platform for testing potential anticancer drugs on patient …

New tools are needed to match cancer patients with effective treatments. Patient-derived
organoids offer a high-throughput platform to personalize treatments and discover novel …

Patient-derived cancer organoids (PCOs) are in vitro organotypic models that reflect in vivo
drug response, thus PCOs are an accessible model for cancer drug screening in a clinically …

Heterogeneous populations within a tumor have varying metabolic profiles, which can
muddle the interpretation of bulk tumor imaging studies of treatment response. Although …

Patient-derived tumor organoids (PDTOs) hold great promise for preclinical and translational
research and predicting the patient therapy response from ex vivo drug screenings …

Head and neck cancer patients suffer from toxicities, morbidities, and mortalities, and these
ailments could be minimized through improved therapies. Drug discovery is a long …

Purpose: Cancer treatment is limited by inaccurate predictors of patient-specific therapeutic
response. Therefore, some patients are exposed to unnecessary side effects and delays in …

Simple Summary Gastroenteropancreatic neuroendocrine tumors (GEP-NET) account for
roughly 60% of all neuroendocrine tumors, and low/intermediate grade human GEP-NETs …